Join donors like David in leading the charge to advance immunotherapy research – Cancer Research Institute (CRI)
“In February 2004, I received a message over the phone no parent ever wants to hear: “Dad, I have a brain tumor.” Later that month, my 28 year-old son Christopher underwent surgery for a plum size mass in his occipital lobe. The diagnosis: glioblastoma multiforme cancer, stage four. He entered a double barrel treatment protocol of chemotherapy and radiation,” David Cicotello shares.
“That summer, Chris was a candidate for a clinical trial involving the patient’s immune system at the L.A. Cedar Sinai Hospital. But the tumor returned, which disqualified him from the trial.
Determined to live with his illness and not be defeated by it, Chris resumed his graduate studies at Claremont School of Theology later that fall. After a year or so of maintenance treatment, he traveled to Israel with a group of theology students in January 2006.
By May, the tumor chickenwired to the frontal lobe, and his condition worsened quickly. Neither further surgery nor treatment was ordered. Surrounded by his loved ones, Chris passed away at home on June 23, 2006. He didn’t suffer.
For 10 years or so, I have contributed only to the Cancer Research Institute, for I am convinced its research and development on immunotherapy offers the best option to treat and cure cancer, including glioblastoma.”
Join donors like David in leading the charge to advance immunotherapy research: https://bit.ly/44of8ML
📸 Photo of Chris, provided by his father, David.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023